8-K current report · filed Nov 16, 2026

CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) 8-K Current Report: November 16, 2026

Item 7.01Item EX-99.1CLOV overview

Short answer

CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) filed an 8-K current report with the SEC on November 16, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Supplemental Q&A published following Clover Health’s third-quarter 2026 earnings announcement.

CLOVER HEALTH INVESTMENTS, CORP. /DE 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Supplemental Q&A published following Clover Health’s third-quarter 2026 earnings announcement
  • Responses address selected shareholder-submitted questions and provide additional investor context
  • Exhibit 99.1 contains the written responses and is available through Clover’s investor relations website

Item EX-99.1 · Exhibit EX-99.1

  • Management sees meaningful earnings leverage through 2028 as 2025-2026 cohorts, roughly half of membership, mature into stronger economics
  • 3Q26 membership reached ~159k, leaving fixed-cost absorption potential and a stated 100-150 basis-point 2026 Adjusted SG&A improvement target
  • Counterpart Assistant evidence includes 18% fewer heart-failure hospitalizations, 25% fewer readmissions, and ~1,500-basis-point historical MCR advantage
  • Counterpart’s commercial opportunity remains difficult to value: contracted lives, implementation schedules, and recurring-revenue outlook withheld
  • New Jersey individual non-SNP share rose from roughly 20% to 31%, supporting continued growth beyond competitor-driven disruption

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other CLOVER HEALTH INVESTMENTS, CORP. /DE 8-K filings

Get the next CLOV 8-K as it lands

Follow CLOV for push alerts, or ask the research agent what this filing means.